HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: fj.07-8697revv1 21/14/3795    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Basavapathruni, A. Articles by Anderson, K. S. Search for Related Content PubMed PubMed Citation Articles by Basavapathruni, A. Articles by Anderson, K. S.

Reverse transcription of the HIV-1 pandemic

Yale University School of Medicine, Department of Pharmacology, New Haven, Connecticut, USA

²Correspondence: Yale University School of Medicine, Department of Pharmacology, SHM B350B, 333 Cedar St., New Haven, CT 06520-8066, USA. E-mail: karen.anderson{at}yale.edu

The HIV/AIDS pandemic has existed for >25 years. Extensive work globally has provided avenues to combat viral infection, but the disease continues to rage on in the human population and infected 4 million people in 2006 alone. In this review, we provide a brief history of HIV/AIDS, followed by analysis of one therapeutic target of HIV-1: its reverse transcriptase (RT). We discuss the biochemical characterization of RT in order to place emphasis on possible avenues of inhibition, which now includes both nucleoside and non-nucleoside modalities. Therapies against RT remain a cornerstone of anti-HIV treatment, but the virus eventually resists inhibition through the selection of drug-resistant RT mutations. Current inhibitors and associated resistance are discussed, with the hopes that new therapeutics can be developed against RT.—Basavapathruni, A., Anderson, K. S. Reverse transcription of the HIV-1 pandemic.

Key Words: resistance • nucleoside • non-nucleoside • AIDS • NRTI removal